Orphazyme A/S (ORPH)
| Market Cap | 209.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -103.81M |
| Shares Out | 34.95M |
| EPS (ttm) | -3.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $5.75 |
| Previous Close | $8.56 |
| Change ($) | -2.81 |
| Change (%) | -32.83% |
| Day's Open | 6.30 |
| Day's Range | 5.75 - 6.62 |
| Day's Volume | 142,987 |
| 52-Week Range | 5.75 - 14.78 |
Orphazyme A/SInvestor news No. 05/2021Company Registration No. 32266355
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease catego...
Orphazyme A S (NASDAQ: ORPH) saw its stock plunge on Monday after failing to meet primary and secondary endpoints in a Phase 2/3 trial. The experimental drug, arimoclomol, was being tested in 150 inclus...
Orphazyme (NASDAQ:ORPH) is currently down 30.59% to a price of $8.75. The stock's current volume for the day is 327.17 thousand, which is approximately 5917.33% of its previous 30-day average volume of ...
Copenhagen – March 29, 2021 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of neurodegenerative rare dise...
Orphazyme A/SCompany announcement No. 10/2021 ...
Orphazyme A/SCompany announcement No. 09/2021 ...
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease catego...
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...
Orphazyme A/S Company announcement No. 06/2021Company Registration No. 32266355
Orphazyme A/SCompany announcement No. 05/2021Inside informationCompany Registration No. 32266355
Orphazyme A/SInvestor news No. 04/2021 ...
Orphazyme A/SInvestor news No. 03/2021 ...
LONDON--(BUSINESS WIRE)---- $ORPH #COVID--Open Orphan (AIM:ORPH) announced the world's first COVID-19 characterization study has received ethics approval in the UK.
Orphazyme USInvestor news No. 02/2021
Copenhagen, Denmark, February 1, 2021 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transac...
Orphazyme A/SCompany announcement No. 02/2021 ...
Orphazyme A/SInvestor news No. 01/2021 ...
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...
Copenhagen, Denmark – December 27, 2020 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan ...
Orphazyme A/SCompany announcement No. 72/2020Inside informationCompany Registration No. 32266355
Global executive team expanding to support growth plans with three U.S.-based leaders
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...
Orphazyme A/SCompany announcement No. 70/2020 ...
Orphazyme A/SCompany announcement No. 67/2020 ...
Due to unfortunate timing, Orphazyme listing on NASDAQ did not go smoothly.
Copenhagen, Denmark, October 2, 2020 – Orphazyme A/S (ORPHA; ORPH) (“Orphazyme”), CVR no. 32266355, a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of...
Orphazyme A/S has today registered a capital increase of new ordinary shares and completed its global offering, consisting of an initial public offering of American Depositary Shares (“ADSs”) in the U.S...
Orphazyme has filed to raise $100 million in a U.S. IPO.
Orphazyme A/SCompany announcement No. 50/2020 ...
Denmark-based Orphazyme A/S has filed to go public in the U.S., but has not yet determined how many shares it will offer.
About ORPH
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, In... [Read more...]
| Industry Pharmaceutical Preparation Manufacturing | IPO Date Sep 29, 2020 |
| CEO Kim Stratton | Employees 141 |
| Stock Exchange NASDAQ | Ticker Symbol ORPH |
Analyst Forecasts
According to 3 analysts, the average rating for Orphazyme stock is "Strong Buy." The 12-month stock price forecast is 18.67, which is an increase of 224.70% from the latest price.